title: Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.
abstract: BACKGROUND
  A 17-year-old Filipino male hemodialysis patient presented for renal transplant evaluation. He had significant skeletal abnormalities characterized by bone pain, an inability to walk, and secondary hyperparathyroidism despite therapy with an active vitamin D sterol (paricalcitol).
  
  
  METHODS
  The patient underwent a physical examination, and his serum levels of calcium, phosphorus, alkaline phosphatase, parathyroid hormone, aluminum and 25-hydroxycholecalciferol (25OH-vitamin D) were determined. X-rays of hips and lower extremities, MRI, and bone histomorphometry after double tetracycline labeling were performed.
  
  
  METHODS
  Osteomalacia associated with low 25OH-vitamin D levels.
  
  
  RESULTS
  Monthly therapy with ergocalciferol (vitamin D2) and discontinuation of paricalcitol.
authors: David Geffen School of Medicine at UCLA, CA, USA.
authors: Joel D
authors: JD
authors: Hernandez
authors: Katherine
authors: K
authors: Wesseling
authors: M Ines
authors: MI
authors: Boechat
authors: Barbara
authors: B
authors: Gales
authors: Isidro B
authors: IB
authors: Salusky
mesh_terms: D000293:Adolescent; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004872:Ergocalciferols / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000150:complications / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D010018:Osteomalacia / Q000097:blood / Q000139:chemically induced*; D006435:Renal Dialysis / Q000009:adverse effects*; D014808:Vitamin D Deficiency / Q000097:blood / Q000139:chemically induced
chemical_list: D050071:Bone Density Conservation Agents; D004872:Ergocalciferols; C084656:paricalcitol